• Home
  • Shop
  • About
  • FAQ
  • Contact
  • Compare Peptides
  • Wholesale
  • AOD-9604 Research: Growth Hormone Fragment Studies

    Research Use Only β€” Informational Content: The information in this article is intended for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. Iron Peak Peptides products are strictly for laboratory and scientific research β€” not for human consumption. Consult a licensed healthcare provider before starting any treatment or therapy. These statements have not been evaluated by the FDA.

    AOD 9604 Peptide Research: Growth Hormone Fragment Studies

    AOD-9604 (Anti-Obesity Drug 9604) is a synthetic fragment of human growth hormone (hGH), specifically corresponding to a modified portion of the C-terminal region spanning amino acids 177-191. This synthetic fragment was designed to isolate particular biological effects such as fat burning, while minimizing the growth-promoting or diabetogenic effects associated with full-length growth hormone. AOD-9604 is often marketed as a fat burning peptide due to its purported ability to accelerate fat breakdown and support fat loss. Originally developed at Monash University in Melbourne, Australia by Professor Frank Ng’s research group, AOD-9604 peptide has been investigated for its lipid metabolism-modulating properties. Metabolic Pharmaceuticals Ltd. played a key role in conducting clinical trials and advancing research on AOD-9604. This article reviews the scientific research on AOD-9604, including its development, mechanism of action, and key findings. The content provided is intended for educational and informational purposes only and does not constitute medical advice. Much of the safety and efficacy information discussed is based on published research and research literature.

    In the United States, AOD 9604 is available in research chemical form and is typically labeled ‘for research purposes only’ to comply with DSHEA regulations. Additionally, AOD 9604 has received GRAS (Generally Recognized as Safe) designation from the FDA for use as a food ingredient, which is a separate regulatory category from drug approval.

    Introduction to AOD-9604

    AOD-9604 is a synthetic peptide derived from the human growth hormone, specifically corresponding to the fragment 176-191 of the full-length molecule. Developed by Metabolic Pharmaceuticals, this peptide was designed to harness the fat metabolism benefits of growth hormone while minimizing the adverse effects commonly associated with traditional GH therapy. Early studies demonstrated the peptide’s potential for fat burning and metabolic benefits, laying the groundwork for further research. Unlike full-length growth hormone, AOD-9604 selectively targets fat oxidation and breakdown, with a particular focus on reducing abdominal fat. Clinical trials have explored its ability to promote weight loss and improve body composition; clinical evidence from human clinical trials indicates that AOD-9604 produces modest fat loss, especially when combined with lifestyle interventions such as caloric management and exercise. These studies also show a neutral impact on insulin sensitivity and growth hormone secretion. As a synthetic peptide derived from human growth hormone, AOD-9604 represents a promising research tool for investigating metabolic pathways and potential interventions for obesity and related metabolic disorders.

    Development and Background

    From Growth Hormone to AOD-9604

    The development of AOD-9604 arose from a fundamental question in growth hormone biology: can the metabolic effects of GH be separated from its growth-promoting effects? Human growth hormone is a 191-amino acid protein that exerts diverse physiological effects including:

    • Linear growth promotion (via IGF-1)

    • Lipolysis (fat metabolism)

    • Protein synthesis stimulation

    • Glucose homeostasis effects

    • Bone metabolism regulation

    Research in the 1990s by Ng and colleagues at Monash University identified that the C-terminal fragment of hGH (amino acids 177-191) retained lipolytic activity while lacking the IGF-1-stimulating and diabetogenic properties of full-length GH. This fragment was then stabilized by the addition of a tyrosine residue at position 177, creating the peptide known as AOD-9604. Early mechanistic studies in obese mice provided key evidence for AOD-9604‘s fat-reducing effects, supporting its potential as a therapeutic agent for weight management.

    Structural Features

    AOD-9604 consists of the 15 amino acids of hGH(177-191) with a modified N-terminus. The key structural features include:

    • Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

    • Disulfide bond: An intramolecular disulfide bond between the two cysteine residues creates a loop structure essential for biological activity

    • N-terminal tyrosine: The added tyrosine stabilizes the peptide and provides a site for iodination in radioligand studies

    Mechanism of Action

    Lipolytic Pathway

    Research has demonstrated that AOD-9604 stimulates lipolysis (the breakdown of triglycerides into glycerol and free fatty acids) in adipose tissue. The proposed mechanism involves:

    1. Beta-3 adrenergic receptor interaction: Studies suggest AOD-9604 may enhance signaling through the Ξ²3-adrenergic pathway in adipocytes

    2. cAMP elevation: Like full-length GH, the fragment appears to increase intracellular cAMP levels in fat cells, activating hormone-sensitive lipase (HSL)

    3. HSL activation: Phosphorylated HSL catalyzes the hydrolysis of stored triglycerides, releasing free fatty acids for oxidation

    4. Lipogenesis inhibition: In addition to promoting fat breakdown, research indicates AOD-9604 may inhibit the synthesis of new fatty acids

    AOD-9604 is also purported to target stubborn fat, particularly visceral (abdominal) fat, which is often resistant to traditional dieting methods. Some studies have reported significant fat loss in preclinical models, especially in areas like the abdomen, hips, and thighs, though results in humans are more modest.

    IGF-1 Independence

    A critical finding that distinguishes AOD-9604 from full-length GH is that the fragment does not bind to the growth hormone receptor, which explains its lack of IGF-1 stimulation. Notably, AOD-9604 also does not increase the risk of carpal tunnel syndrome, a condition often associated with full-length growth hormone due to fluid retention and tissue swelling. This is significant because many of GH’s growth-promoting and potentially adverse effects are mediated through IGF-1 and insulin like growth pathways. Across all six clinical trials, AOD 9604 demonstrated a favorable safety profile, with no serious adverse events reported and no significant changes in glucose or IGF-1 levels.

    Glycemic Neutrality

    Full-length growth hormone can impair insulin sensitivity and raise blood glucose levels β€” effects that have limited its utility as a metabolic research tool. In contrast, AOD-9604 has been shown not to worsen insulin resistance, making it a safer option for individuals with concerns about metabolic syndrome. Studies have shown that AOD-9604 does not share these diabetogenic properties. This glycemic neutrality is particularly important for research subjects with underlying metabolic syndrome or insulin resistance.

    Key Research Studies

    In Vitro Lipolysis Studies

    Early in vitro research established AOD-9604‘s lipolytic activity. The lipolytic potency was comparable to that of full-length GH on a molar basis, confirming that the C-terminal fragment retained the lipolytic activity of the parent molecule.

    Obese Mouse Model Studies

    Research by Heffernan et al. published in Endocrinology examined AOD-9604 in ob/ob mice (a genetic model of obesity). The study reported that chronic AOD-9604 administration reduced body weight gain and adipose tissue mass without affecting food intake, lean body mass, or IGF-1 levels. This selective reduction in fat mass without lean tissue effects was consistent with the proposed mechanism of enhanced lipolysis.

    Obese Zucker Rat Studies

    Additional animal model research in Zucker fatty rats confirmed the lipolytic effects observed in mouse studies. AOD-9604 treatment reduced body fat percentage and modulated lipid metabolism markers without altering growth rate or producing the hyperglycemia associated with GH treatment.

    Cartilage and Joint Research

    An emerging area of AOD-9604 research involves its potential effects on cartilage metabolism. Studies have investigated whether the GH fragment can stimulate chondrocyte proliferation and proteoglycan synthesis. Research published in Journal of Musculoskeletal Research reported that AOD-9604 enhanced chondrocyte activity in vitro, leading to its investigation as a potential research tool for studying cartilage biology. AOD-9604 has received regulatory designations in some jurisdictions for further investigation in this area.

    Clinical Use

    AOD 9604, a synthetic fragment of human growth hormone, has been explored in clinical settings for its potential to support fat metabolism and promote weight loss. Clinical trials have shown that AOD 9604 can enhance fat breakdown and increase fat oxidation, resulting in statistically significant weight loss in certain study populations. Despite these findings, AOD 9604 remains a research compound and is not approved for weight loss or any other therapeutic indication. Its use in any clinical context should be overseen by a qualified healthcare provider, with careful consideration of individual health status and adherence to current medical guidelines. As a synthetic fragment of growth hormone, AOD 9604 continues to be a subject of interest for researchers investigating novel approaches to fat metabolism and body composition management.

    Regulatory Status

    AOD 9604 is not approved for any medical use, including weight loss or fat metabolism support. While it has achieved Generally Recognized as Safe (GRAS) status as a food ingredient, this designation does not extend to therapeutic or clinical applications. The clinical development of AOD 9604 was discontinued in 2007 after studies failed to demonstrate statistically significant weight loss compared to placebo, though research into its safety profile and metabolic effects continues. Use of AOD 9604 as a peptide research should always be discussed with a licensed medical professional, as regulations may vary by jurisdiction. Additionally, AOD 9604 is listed as a prohibited substance by the World Anti-Doping Agency (WADA), and its use in competitive sports can result in sanctions or positive doping tests. Researchers must remain informed about current regulatory guidelines and ensure compliance when working with this compound.

    AOD-9604 vs. Related Compounds

    Compound

    Origin

    IGF-1 Effects

    Lipolytic Activity

    Glucose Effects

    hGH (full-length)

    191 amino acids

    Increases IGF-1

    Yes

    May impair glucose tolerance

    AOD-9604

    hGH(177-191) fragment

    No IGF-1 effect

    Yes

    Glycemic neutral

    hGH Fragment 176-191

    hGH fragment (no Tyr)

    No IGF-1 effect

    Yes (lower)

    Glycemic neutral

    Ipamorelin

    GH secretagogue

    Increases IGF-1 (via GH) through growth hormone release

    Indirect

    Minimal

    Note: When evaluating any peptide protocol, including AOD-9604, it is essential to consider the safety profile and available clinical trial data. Peptides such as CJC-1295 and Ipamorelin stimulate growth hormone release via GHRH and ghrelin receptor pathways, which can result in different metabolic effects compared to AOD-9604.

    Research Applications

    AOD-9604 is utilized in various research contexts, with applications and findings supported by published research and research literature:

    • Adipocyte biology: Studying lipolytic signaling pathways in fat cells

    • Metabolic research: Investigating lipid metabolism modulation independent of IGF-1

    • Structure-activity studies: Understanding which regions of GH mediate specific biological effects

    • Cartilage research: Examining effects on chondrocyte biology and proteoglycan synthesis

    • Comparative pharmacology: Comparing metabolic effects of GH fragments vs. full-length GH and GH secretagogues

    Iron Peak Peptides offers AOD-9604 5mg at high quality, with full analytical documentation for research applications.

    Future Directions

    There is growing interest in exploring how AOD-9604 might be combined with other peptide research areas, such as GLP-1 agonists or growth hormone-releasing peptides, to achieve synergistic effects on body composition and metabolic parameters. As peptide research continues to evolve, AOD-9604 could become an important tool for supporting fat metabolism and improving body composition goals. However, it is important to note that AOD-9604 is not currently approved for clinical use. Any application in a clinical setting should be overseen by a qualified healthcare provider, with careful consideration of individual health status and ongoing safety monitoring.

    Frequently Asked Questions

    What is AOD-9604 and where does it come from?

    AOD-9604 is a synthetic peptide corresponding to a modified fragment (amino acids 177-191) of human growth hormone. It was developed at Monash University in Australia by Professor Frank Ng’s research group. The peptide retains the lipolytic properties of full-length GH without its growth-promoting or diabetogenic effects.

    How does AOD-9604 differ from full-length growth hormone?

    Unlike full-length GH, AOD-9604 does not stimulate IGF-1 production, does not promote linear growth, and does not impair glucose tolerance. It selectively retains the lipolytic (fat-metabolizing) activity of the C-terminal region of GH while lacking the broader hormonal effects mediated through the GH receptor’s full activation.

    Does AOD-9604 affect insulin or blood sugar in research models?

    This contrasts with full-length GH, which can impair glucose tolerance.

    What is the connection between AOD-9604 and cartilage research?

    Emerging research has identified that AOD-9604 may stimulate chondrocyte proliferation and proteoglycan synthesis. Studies have shown effects on cartilage metabolism in vitro, leading to regulatory interest in investigating AOD-9604‘s potential role in cartilage biology research.

    Research Purposes Only Disclaimer

    All products and information presented in this article are intended for research purposes only. AOD-9604 is a research peptide not intended for human consumption, therapeutic use, or as a dietary supplement. The scientific findings discussed are from preclinical and clinical research studies and should not be interpreted as therapeutic recommendations. Iron Peak Peptides supplies AOD-9604 exclusively for in vitro and laboratory research. Researchers must comply with all applicable regulations governing the purchase and use of research materials.


    Browse Our Research Peptide Catalog

    Iron Peak Peptides offers 28+ premium research-grade peptides, all with high quality verification and quality assurance. Every batch is independently tested by accredited laboratories.

    β†’ View Full Product Catalog

    Popular research peptides: BPC-157 Β· Semaglutide Β· Tirzepatide Β· TB-500 Β· Ipamorelin

    All products are for research use only. Not intended for human consumption.

    Related Research


    IronPeak ships nationwide to labs in California, researchers in Texas, and New York laboratories.

    ← Semax and Selank: Nootropic Peptide Research Compared
    Research Peptides vs. Pharmaceutical Peptides: Key Differences β†’